AUTHOR + STRATEGIST

SergeyVlasenko, Ph.D.

More than twenty-five years in diagnostics, life-science tools, and biopharma — from immunoassay R&D at Bio-Rad, to CEO of ProZyme through its acquisition by Agilent, to biopharma strategy inside Agilent’s global platform, to strategy and partnerships inside China’s diagnostics ecosystem at Fapon. He writes about the systems that turn scientific possibility into durable categories.

Sergey Vlasenko

THE PERSPECTIVE

Writing from where science meets the system.

Sergey began in high-sensitivity immunoassay R&D at Bio-Rad’s Clinical Diagnostics Group, where he learned that a measurement is not yet a category. He has since run a life-science company through acquisition, built biopharma strategy inside a global instruments company, and now works on partnerships and strategy from within China’s diagnostics ecosystem — four sides of the same question.

His books examine the places where elegant science meets institutional reality: where technology must become workflow, proof must become trust, invention must become procurement, and a product must become an operating system.

EXPERIENCE IN CONTEXT

Built across science, strategy, and operations.

01BIO-RAD

Building diagnostics and biopharma businesses

Technical and strategic leadership across clinical diagnostics systems, life-science tools, and biopharma workflows.

02PROZYME

Leading through an exit

CEO of a Bay Area life-science company through its acquisition by Agilent — where a technical promise met a market.

03AGILENT

Enterprise market strategy

Global biopharma market strategy across North America and Europe, supporting expansion in China.

04FAPON

Strategy across ecosystems

Strategy and partnerships inside China’s diagnostics ecosystem — the vantage point behind the China argument across all three books.

THE BOOKS

Follow the category from formation to control.

Explore the books